The Myasthenia Gravis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Myasthenia Gravis: An Overview
Myasthenia gravis (MG) is a neurological autoimmune disease mediated by antibodies against postsynaptic antigens of the neuromuscular junction. The main clinical feature of the disease is the presence of fatigability or muscle weakness that worsens with exercise. The disease is very heterogeneous from an immunological point of view.
Myasthenia Gravis is typically divided into five types, congenital myasthenia gravis, generalized myasthenia gravis, ocular myasthenia gravis, transient neonatal myasthenia gravis, and juvenile myasthenia gravis, depending on the time of disease onset, the cause of the neuromuscular dysfunction, and the muscle groups affected.
Myasthenia Gravis Treatment includes medication and/or surgery. Medication consists mainly of acetylcholinesterase inhibitors to directly improve muscle function and immunosuppressant drugs to reduce the autoimmune process. Thymectomy is a surgical method to treat MG.
Myasthenia Gravis Market Key Facts
-
The prevalence of myasthenia gravis in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the United States. However, myasthenia gravis remains underdiagnosed and the prevalence is probably higher (James et al.)
-
As per DelveInsight estimates, total cases of Generalized Myasthenia Gravis in the 7MM were found to be 58,800+ in 2017.
-
Among all the countries, the estimates show a higher diagnosed prevalence of generalized Myasthenia Gravis in the United States in 2017. While Japan had the lowest diagnosed prevalent population of Myasthenia Gravis in 2017.
-
Among the total prevalent cases, moderate to severe generalized cases were more as compared to the mild and intubated cases.
The Myasthenia Gravis (MG) Market Size is anticipated to increase during the study period owing to the increase in prevalent cases of MG and the impact of effective treatment, improved diagnostic methods, and prolonged survival from the disease,
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Myasthenia Gravis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Myasthenia Gravis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Myasthenia Gravis Epidemiology
The epidemiology section covers insights about the historical and current Myasthenia Gravis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Myasthenia Gravis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myasthenia Gravis market or expected to get launched in the market during the study period. The analysis covers Myasthenia Gravis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Myasthenia Gravis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/myasthenia-gravis-market
Myasthenia Gravis Therapeutics Analysis
The Myasthenia Gravis Pipeline is crowded, with several potential therapies as many companies are working robustly on developing many new therapies for MG.
Myasthenia Gravis Companies:
-
Takeda
-
Argenx
-
Immunovant
-
UCB Pharma
-
CSL Behring
-
Ra Pharmaceuticals
-
Alexion Pharmaceuticals
-
Momenta Pharmaceuticals
-
Catalyst Pharmaceuticals
And many others.
Myasthenia Gravis Therapies covered in the report include:
-
Firdapse
-
Hizentra
-
Rozanolixizumab
-
Efgartigimod
-
Zilucoplan
-
Ravulizumab
-
IMVT-1401
-
M281
-
TAK-079
And many others.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/myasthenia-gravis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Myasthenia Gravis Competitive Intelligence Analysis
4. Myasthenia Gravis Market Overview at a Glance
5. Myasthenia Gravis Disease Background and Overview
6. Myasthenia Gravis Patient Journey
7. Myasthenia Gravis Epidemiology and Patient Population
8. Myasthenia Gravis Treatment Algorithm, Current Treatment, and Medical Practices
9. Myasthenia Gravis Unmet Needs
10. Key Endpoints of Myasthenia Gravis Treatment
11. Myasthenia Gravis Marketed Products
12. Myasthenia Gravis Emerging Therapies
13. Myasthenia Gravis Seven Major Market Analysis
14. Attribute Analysis
15. Myasthenia Gravis Market Outlook (7 major markets)
16. Myasthenia Gravis Access and Reimbursement Overview
17. KOL Views on the Myasthenia Gravis Market.
18. Myasthenia Gravis Market Drivers
19. Myasthenia Gravis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/myasthenia-gravis-market
Trending Healthcare Reports By DelveInsight
Injectable Drug Delivery Devices Market
The Global Injectable Drug Delivery Devices Market is expected to reach USD 33.37 billion by 2026. Some of the key MedTech companies such Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others, are actively working in the Injectable Drug Delivery Devices Market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/